Peptides in 2026: how much human evidence sits behind each one
BPC-157, TB-500, CJC-1295 and ipamorelin are being sold and injected far ahead of the literature. We counted the published studies for each and separated the ones done in people.
Peptides became a wellness product before they became a body of evidence. That gap is the whole story, and it is measurable: PubMed will tell you how many studies exist for a compound, and how many of them involved humans rather than cells or rodents.
We pulled those counts on 2026-08-29. The dark bar is human studies. The pale bar behind it is everything ever published on the compound.
| Peptide | All studies | Human studies | Human share | PubMed term |
|---|---|---|---|---|
| CJC-1295 | 33 | 21 | 64% | "CJC-1295" |
| Ipamorelin | 54 | 28 | 52% | ipamorelin |
| GHK-Cu | 122 | 51 | 42% | "GHK-Cu" OR "GHK copper" |
| BPC-157 | 227 | 53 | 23% | BPC-157 OR "BPC 157" |
| PDRN (skin) | 128 | 71 | 55% | (polydeoxyribonucleotide OR PDRN) AND skin |
| TB-500 / thymosin beta-4 | 1,074 | 605 | 56% | "TB-500" OR thymosin beta-4 |
CJC-1295 has 33 published studies in total, and 21 of them involved humans. Ipamorelin has 54 and 28. For scale, resveratrol — a compound most people would call under-evidenced — carries 21,601 papers.
BPC-157 is the case worth pausing on. It carries 227 studies, which sounds substantial until you see that 53 involved humans. The animal literature is genuinely large. The human literature is not, and the two get quoted as though they were the same thing.
TB-500 looks stronger at 605 human studies, but that figure covers the whole thymosin beta-4 literature, much of it unrelated to how the peptide is sold today. A large number in a database is not evidence for the dose, route and purpose being offered to you.
What a study count does not tell you
Counts measure attention, not quality. Fifty small uncontrolled reports and one large randomised trial look identical here and mean very different things. Read this as a floor: if a compound has fewer than thirty human papers in total, no amount of confident marketing changes that.
Regulatory status is a separate question. A compound can be widely studied and still not be authorised for the use being sold, in any jurisdiction. Ask what is approved, by which authority, and for which indication.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.